Metformin Sandoz (Metformin Hydrochloride)

Metformin acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), enhancing peripheral glucose uptake and improving insulin sensitivity without stimulating insulin secretion.

The dosage of Metformin Sandoz is individualized by the prescribing clinician based on the patient’s clinical status, renal function, and glycemic goals. The prescriber determines the appropriate starting dose and any subsequent titration according to standard therapeutic guidelines.

Metformin’s pregnancy category is listed as unknown, and its safety has not been fully established. It is generally avoided during pregnancy unless the potential benefit justifies the risk. Limited data suggest it may be excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Metformin Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin belongs to the biguanide class and is often preferred as first‑line therapy because it does not cause hypoglycemia when used alone and may promote modest weight loss. In contrast, sulfonylureas increase insulin secretion and carry a higher hypoglycemia risk, while newer agents such as GLP‑1 agonists provide weight loss but are injectable and more costly.

Metformin Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Metformin Sandoz is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not crush or split extended‑release formulations unless instructed.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions causing hypoxia. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant vitamin B12 deficiency with long‑term use.

Metformin Sandoz is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those receiving iodinated contrast agents for imaging studies without appropriate renal monitoring.